Skip Navigation LinksHome > December 2008 - Volume 109 - Issue 6 > β3-Adrenergic Receptor Subtype Signaling In Senescent Heart:...
doi: 10.1097/ALN.0b013e31818d4942
Editorial Views

β3-Adrenergic Receptor Subtype Signaling In Senescent Heart: Nitric Oxide Intoxication or “Endogenous” β Blockade for Protection?

Zaugg, Michael M.D., D.E.A.A., F.R.C.P.C.*; Schaub, Marcus C. M.D., Ph.D.†

Free Access
Article Outline
Collapse Box

Author Information

COMPLEX biochemical, pharmacologic, and physiologic changes occur with advancing age in the myocardium. These changes may be subtle and virtually undetectable under resting steady state conditions, but become prominent under stressful stimulation. In this issue of Anesthesiology, Birenbaum et al.1 provide evidence for impaired inotropic response (approximately 30%) to β-adrenergic stimulation in aged versus young rat hearts. Apart from β1-adreneric receptor (AR) down-regulation, they further demonstrate that increased formation of nitric oxide deriving from neuronal nitric oxide synthase (nNOS) via the activated β3-AR subtype signaling pathway is responsible for the reduced inotropy in senescent hearts.
Table 1
Table 1
Image Tools
Fig. 1
Fig. 1
Image Tools
Since the late 1980s, it is known that three β-AR subtypes, namely the β1-, β2-, and β3-AR, participate in the regulation of cardiovascular function. Expression of β3-ARs in human hearts was first reported in 1996 by Gauthier et al.2 The β3-AR shares only approximately 50% homology with β1/2-ARs and is particular in certain aspects (table 1). First, in contrast to β1/2-ARs (monoexonic genes), the gene encoding this receptor on chromosome 8 contains two exons and one intron enabling alternative splicing and formation of two different receptor isoforms with different pharmacologic properties.3 Second, the β3-AR lacks phosphorylation sites for G protein–coupled receptor kinase and protein kinase A in the cytoplasmic C-terminus tail, and thus is resistant to catecholamine-induced desensitization.4 Third, besides the strong lusitropic effects, the majority of studies suggest inhibition of cardiac contractility after β3-AR stimulation. Hence, in the presence of labetalol or prazosin plus nadolol, i.e., α- plus β1/2-AR blockade, norepinephrine becomes cardiodepressive.5 In cardiomyocytes (fig. 1), β3-ARs activate, through a pertussis toxin–sensitive Gi protein–coupled mechanism, endothelial nitric oxide synthase (eNOS or NOS3), located between sarcolemmal and T-tubular caveolae, and nNOS (or NOS1), located in the sarcoplasmic reticulum (or sarcolemma in the failing heart), and exert nitric oxide–mediated negative inotropic effects via the guanylyl cyclase–cyclic guanosine monophosphate pathway on L-type Ca2+ channels and on myofilaments.5–8 Nitric oxide further inhibits contractility by S-nitrosylation of key proteins of the respiratory chain,9 energy metabolism,10 contractile apparatus, and Ca2+ handling, and it potentiates the inhibitory effect of the Gi protein on protein kinase A by activating phosphodiesterase II,11 thereby reducing the second messenger cyclic adenosine monophosphate of the Gs-coupled β1/2-ARs. A last feature of the β3-AR is its low expression in healthy myocardium with a preference in left ventricular tissue, while its expression is reported to increase by two to three times in various pathologic conditions including sepsis,12 diabetes,13 and heart failure14 and, as shown in the current study by Birenbaum et al.,1 during the aging process.
In perioperative medicine, the sympathetic nervous system plays an important role in the pathogenesis of cardiovascular complications.15 Therefore, gaining control over the adrenergic activity represents a core task in anesthetic practice.16,17 On the other side, sustained activation of the sympathetic nervous system with enhanced β-AR signaling plays an important role in cardiovascular aging by promoting inflammation, oxidation and nitrosylation of key proteins, and cell death.18 Consistent with the free radical theory of aging, previous studies showed increased formation of reactive oxygen and nitrogen species in aged myocardium, mainly generated by mitochondria and nitric oxide synthase (NOS) isoforms.19 Nitric oxide is produced by nearly all cell types in the heart, and is synthesized from l-arginine by the catalytic reaction of the three different highly compartmentalized isoforms of nitric oxide synthase (neuronal or type 1 NOS [nNOS or NOS1], inducible or type 2 NOS [iNOS or NOS2], and endothelial or type 3 NOS [eNOS or NOS3]).20 In the aged heart, iNOS and nNOS, mainly found in cardiomyocytes and autonomic nerves, are up-regulated, whereas eNOS, primarily expressed in endothelial cells (but also myocytes), is down-regulated.21,22 In the adult heart, nitric oxide regulates cardiac biology by affecting energy metabolism, substrate utilization, apoptosis, hypertrophy, regeneration, and preconditioning.23 However, its biologic effects are often “double-edged,” with a variety of opposing effects depending on the dose and site of action within the cell. Li et al.24 demonstrated the deleterious effects of nitric oxide derived from up-regulated iNOS in isolated perfused aged versus young rat hearts. These authors found increased nitric oxide and peroxynitrite formation deriving from up-regulated iNOS, which aggravated postischemic cardiac dysfunction and enlarged infarct size under β-AR stimulation with isoproterenol in aged versus young hearts. nNOS expression was also increased in aged hearts in that study, but its contribution to isoproterenol-induced postischemic damage was not investigated. Nonetheless, this study provides evidence that a phenotypic change of NOS isoforms in aged hearts may predispose to increased myocardial damage under sympathetic tone. As can be speculated from the results by Birenbaum et al.,1 the observed detrimental effect in the study of Li et al.24 may be well explained by upregulation of β3-ARs. Augmented cardiac nitric oxide formation by β3-AR signaling was also reported to be deleterious in sepsis, where the release of endogenous inflammatory mediators such as tumor necrosis factor α and interleukin 1β dramatically decrease the responsiveness of cardiomyocytes to catecholamines.12 Interestingly, this refractoriness to catecholamines is absent in septic β3-AR knockout mice.12 In contrast to the toxic effects of β3-AR signaling in certain conditions, in healthy adult hearts, β3-AR signaling is necessary to counteract the proarrhythmogenic, and otherwise unchained chronotropic, dromotropic, and inotropic effects of β1/2-ARs.8 This phylogenetically highly conserved and protective negative feedback loop against catecholamine toxicity is important for a balanced and fine-tuned contractility.8 Generally speaking, β3-AR signaling acts as a countervailing “brake” against adrenergic overstimulation comparable with an “endogenous” β blockade. This concept is further supported by the fact that β3-ARs maintain cardiac sympathovagal balance by reinforcing vagal tone. Beyond these benefits, but in contrast to pure β blockade, nitric oxide from β3-AR signaling further exerts coronary and peripheral vasodilatation, and may have “pleiotropic” effects on cardiac stem cell biology25 and the prevention of arteriosclerosis.26 Indeed, the “pharmacologic profile” of β3-AR signaling strongly reminds of the one observed with the novel third-generation β-blocker nebivolol, which promotes nitric oxide formation.27 Research in the field of heart failure also supports the idea that β3-AR signaling is beneficial rather than detrimental. In the failing heart, the β3-AR response is preserved even under sustained activation of the adrenergic system and thus antagonizes catecholamine toxicity. However, this does not exclude that adverse effects do occur from β3-AR–mediated negative inotropy, particularly during the progression of heart failure. Interestingly, β3-AR knockout mice show increased SERCA2a expression and phospholamban phosphorylation resulting in enhanced SERCA2a activity.28 Hence, one could speculate that β3-AR blockade could play a salutary role in the therapy of heart failure, at least at later stages of the disease. Together, the biologic consequences of enhanced β3-AR signaling range from “nitric oxide intoxication” on one side to protection comparable to some sort of “physiologic” or “endogenous” β-blockade on the other side. Although the study by Birenbaum et al.1 shows undesirable short-term effects of enhanced β3-AR signaling on inotropy in aged hearts, the biologic (long-term) consequences of this pathway remain elusive.
A number of important questions need to be addressed in future studies before we can translate the findings of Birenbaum et al. to the clinical arena. First, based on genome-wide transcriptional profiling, the molecular mechanisms involved in reduced β-adrenergic responsiveness in the aged heart seem to be more complex and not just confined to a single signaling pathway. Accordingly, Dobson et al.29 reported up-regulation of 19 transcripts involved in age-related antiadrenergic activity, including adenosine A1, muscarinic M3, and nicotinic β3 acetylcholine receptors, and many more. Second, female tissue was reported to express less β3-ARs,30 and nitric oxide is differentially regulated in male and female hearts, as evidenced in nNOS knockout mice, where males develop more pronounced cardiac remodeling than females.31 Therefore, sex-based differences may be of relevance in β3-AR and nitric oxide signaling, specifically in aged hearts. Third, although the rat and human β3-AR share 79% identity, there are pronounced heterogeneous pharmacologic profiles of β3-AR agonists/antagonists between different species. Therefore, caution must be applied in extrapolating data obtained from rat hearts to human myocardium. Finally, β3-ARs are also expressed in vessels. Namely, β3-ARs are expressed on the endothelium of coronary microarteries,32 but their role in ischemia–reperfusion is unknown, and it is unclear, to date, whether vascular β3-ARs are similarly up-regulated during the aging process.
Modulation of β3-AR signaling in the diseased heart in general and in the senescent heart in particular opens new therapeutic approaches. However, much research is required to fully understand the complexity of β-AR biology with its contrasting influences. New compounds with β3-AR agonistic and/or antagonistic properties could help to better modulate and control the adrenergic system in the perioperative period. For example, in coronary artery bypass graft surgery patients, there is β1/2-AR but not β3-AR dysfunction after cardiopulmonary bypass, and β3-AR stimulation could increase graft flow, decrease oxygen consumption, and thus protect the heart. However, these effects must be carefully balanced against the negative inotropy of β3-AR signaling. Interestingly, the single nucleotide polymorphism of the β3-AR at codon 64 from tryptophan to arginine was found to be associated with insulin resistance, diabetes, obesity, and hypertension.8 Hence, patient studies investigating the impact of β-AR genomics on cardiac biology and clinical outcome might help to discern the therapeutic potential of β3-AR signaling in the context of other important adrenergic polymorphisms33 in human heart disease. Clearly, the findings by Birenbaum et al.1 are important and will stimulate future research aiming at improving the cardiovascular management of elderly surgical at-risk patients. In this challenging endeavor, however, we need to expand our understanding of complex β-AR signaling beyond the platitude that “it is not by the gray of the hair that one knows the age of the heart” (Robert Bulwer-Lytton).
Michael Zaugg, M.D., D.E.A.A., F.R.C.P.C.,*
Marcus C. Schaub, M.D., Ph.D.†
*Department of Anesthesiology and Pain Medicine, University of Alberta, and Perioperative Translational Medicine, Mazankowski Alberta Heart Institute, Edmonton, Canada. †Institute of Pharmacology, University of Zurich, Switzerland.
Back to Top | Article Outline


1. Birenbaum A, Tesse A, Loyer X, Michelet P, Andriantsitohaina R, Heymes C, Riou B, Amour J: Involvement of β3-adrenoceptor in altered β-adrenergic response in senescent heart: Role of nitric oxide synthase 1–derived nitric oxide. Anesthesiology 2008; 109:1045–53

2. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H: Functional beta3-adrenoceptor in the human heart. J Clin Invest 1996; 98:556–62

3. Granneman JG, Lahners KN, Rao DD: Rodent and human beta 3-adrenergic receptor genes contain an intron within the protein-coding block. Mol Pharmacol 1992; 42:964–70

4. Liggett SB, Freedman NJ, Schwinn DA, Lefkowitz RJ: Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-adrenergic receptor. Proc Natl Acad Sci U S A 1993; 90:3665–9

5. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le Marec H: The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998; 102:1377–84

6. Shah AM, Spurgeon HA, Sollott SJ, Talo A, Lakatta EG: 8-Bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes. Circ Res 1994; 74:970–8

7. Yasuda S, Lew WY: Lipopolysaccharide depresses cardiac contractility and beta-adrenergic contractile response by decreasing myofilament response to Ca2+ in cardiac myocytes. Circ Res 1997; 81:1011–20

8. Rozec B, Gauthier C: Beta3-adrenoceptors in the cardiovascular system: Putative roles in human pathologies. Pharmacol Ther 2006; 111:652–73

9. Torres J, Darley-Usmar V, Wilson MT: Inhibition of cytochrome c oxidase in turnover by nitric oxide: Mechanism and implications for control of respiration. Biochem J 1995; 312(pt 1):169–73

10. Gross WL, Bak MI, Ingwall JS, Arstall MA, Smith TW, Balligand JL, Kelly RA: Nitric oxide inhibits creatine kinase and regulates rat heart contractile reserve. Proc Natl Acad Sci U S A 1996; 93:5604–9

11. Beavo JA: cGMP inhibition of heart phosphodiesterase: Is it clinically relevant? J Clin Invest 1995; 95:445

12. Moniotte S, Belge C, Sekkali B, Massion PB, Rozec B, Dessy C, Balligand JL: Sepsis is associated with an upregulation of functional beta3 adrenoceptors in the myocardium. Eur J Heart Fail 2007; 9:1163–71

13. Amour J, Loyer X, Le Guen M, Mabrouk N, David JS, Camors E, Carusio N, Vivien B, Andriantsitohaina R, Heymes C, Riou B: Altered contractile response due to increased β3-adrenoceptor stimulation in diabetic cardiomyopathy: the role of nitric oxide synthase 1–derived nitric oxide. Anesthesiology 2007; 107:452–60

14. Moniotte S, Vaerman JL, Kockx MM, Larrouy D, Langin D, Noirhomme P, Balligand JL: Real-time RT-PCR for the detection of beta-adrenoceptor messenger RNAs in small human endomyocardial biopsies. J Mol Cell Cardiol 2001; 33:2121–33

15. Zaugg M, Schaub MC: Cellular mechanisms in sympatho-modulation of the heart. Br J Anaesth 2004; 93:34–52

16. Zaugg M, Schulz C, Wacker J, Schaub MC: Sympatho-modulatory therapies in perioperative medicine. Br J Anaesth 2004; 93:53–62

17. Zaugg M, Schaub MC: Genetic modulation of adrenergic activity in the heart and vasculature: Implications for perioperative medicine. Anesthesiology 2005; 102:429–46

18. Zaugg M, Xu W, Lucchinetti E, Shafiq SA, Jamali NZ, Siddiqui MA: Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Circulation 2000; 102:344–50

19. Csiszar A, Pacher P, Kaley G, Ungvari Z: Role of oxidative and nitrosative stress, longevity genes and poly(ADP-ribose) polymerase in cardiovascular dysfunction associated with aging. Curr Vasc Pharmacol 2005; 3:285–91

20. Massion PB, Pelat M, Belge C, Balligand JL: Regulation of the mammalian heart function by nitric oxide. Comp Biochem Physiol A Mol Integr Physiol 2005; 142:144–50

21. Cernadas MR, Sanchez de Miguel L, Garcia-Duran M, Gonzalez-Fernandez F, Millas I, Monton M, Rodrigo J, Rico L, Fernandez P, de Frutos T, Rodriguez-Feo JA, Guerra J, Caramelo C, Casado S, Lopez F: Expression of constitutive and inducible nitric oxide synthases in the vascular wall of young and aging rats. Circ Res 1998; 83:279–86

22. Csiszar A, Ungvari Z, Edwards JG, Kaminski P, Wolin MS, Koller A, Kaley G: Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res 2002; 90:1159–66

23. Seddon M, Shah AM, Casadei B: Cardiomyocytes as effectors of nitric oxide signalling. Cardiovasc Res 2007; 75:315–26

24. Li D, Qu Y, Tao L, Liu H, Hu A, Gao F, Sharifi-Azad S, Grunwald Z, Ma XL, Sun JZ: Inhibition of iNOS protects the aging heart against beta-adrenergic receptor stimulation-induced cardiac dysfunction and myocardial ischemic injury. J Surg Res 2006; 131:64–72

25. Iwakura A, Shastry S, Luedemann C, Hamada H, Kawamoto A, Kishore R, Zhu Y, Qin G, Silver M, Thorne T, Eaton L, Masuda H, Asahara T, Losordo DW: Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 2006; 113:1605–14

26. Mayr U, Zou Y, Zhang Z, Dietrich H, Hu Y, Xu Q: Accelerated arteriosclerosis of vein grafts in inducible NO synthase(−/−) mice is related to decreased endothelial progenitor cell repair. Circ Res 2006; 98:412–20

27. Maffei A, DiPardo A, Carangi R, Carullo P, Poulet R, Gentile MT, Vecchione C, Lembo G: Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension 2007; 50:652–6

28. Ziskoven C, Grafweg S, Bolck B, Wiesner RJ, Jimenez M, Giacobino JP, Bloch W, Schwinger RH, Brixius K: Increased Ca2+ sensitivity and protein expression of SERCA 2a in situations of chronic beta3-adrenoceptor deficiency. Pflugers Arch 2007; 453:443–53

29. Dobson JG Jr, Fray J, Leonard JL, Pratt RE: Molecular mechanisms of reduced beta-adrenergic signaling in the aged heart as revealed by genomic profiling. Physiol Genomics 2003; 15:142–7

30. Rodriguez E, Monjo M, Rodriguez-Cuenca S, Pujol E, Amengual B, Roca P, Palou A: Sexual dimorphism in the adrenergic control of rat brown adipose tissue response to overfeeding. Pflugers Arch 2001; 442:396–403

31. Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S, Casadei B: nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. Circulation 2005; 112:3729–37

32. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL: Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 2004; 110:948–54

33. Zaugg M, Bestmann L, Wacker J, Lucchinetti E, Boltres A, Schulz C, Hersberger M, Kalin G, Furrer L, Hofer C, Blumenthal S, Muller A, Zollinger A, Spahn DR, Borgeat A: Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: The Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: A double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. Anesthesiology 2007; 107:33–44

34. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB: Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59:297–309

35. Reiter MJ: Cardiovascular drug class specificity: Beta-blockers. Prog Cardiovasc Dis 2004; 47:11–33

© 2008 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.

Article Tools